CT Communications, Inc.

Windstream Reports Third-Quarter Earnings Results [Press Release]
Business Wire | 13 days 19 minutes ago
Windstream Corporation (NYSE: WIN) today reported third-quarter earnings results highlighted by the lowest absolute access line loss since the company’s formation in 2006.

Patch Continues to Expand Its Stable of Community Websites by Launching in Summit, New Jersey and Darien, Connecticut [Press Release]
PRNewswire | 94 days 18 hours 15 minutes ago
...publisher for all Patch sites in the NY/NJ/CT tri-state area. "I'm excited about...and Summit, NJ; and Darien and Wilton, CT. CONTACT: Gladwyn Lopez, Rubenstein Communications, Inc, Public Relations,+1-212-843-9231...

Choyce Peterson Goes the Extra Mile for Visiting Nurses [Press Release]
PRNewswire | 38 days 17 hours 32 minutes ago
...Choyce Peterson, Inc. ( www.choycepeterson...Hospice Care of Southwestern CT (VNHC), has moved into...Main Street, Stamford, CT 06902. Contact: Jeff...Gissen Choyce Peterson, Inc. Cut-It-Out Communications, Inc. 203-961-8173...

Choyce Peterson Assists Spruce Private Investors with New Relocation [Press Release]
PRNewswire | 87 days 22 hours 15 minutes ago
...Choyce Peterson, Inc. (www.choycepeterson...Stamford Plaza, Stamford, CT. The new headquarters...Main Street, Stamford, CT 06902 for more information...Gissen Choyce Peterson, Inc. Cut-It-Out Communications, Inc. +1-203-961...

FDA Approves New Use for Micardis(R) in Cardiovascular Risk Reduction and Twynsta(R) as New Combination Treatment for High Blood Pressure [Press Release]
PRNewswire | 33 days 18 hours 47 minutes ago
RIDGEFIELD, Conn., Oct. 19 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis

Video: Budding Videographers Vividly Portray Life with Diabetes to Mark World Diabetes Day [Press Release]
PRNewswire | 11 days 17 hours 17 minutes ago
RIDGEFIELD, Conn., Nov. 10 /PRNewswire/ -- Today ten people with diabetes from across the U.S. and as far as South America were honored for their moving portrayal of how this chronic condition impacts their everyday life through the

Boehringer Ingelheim's Diabetes Pipeline Continues to Advance as the Company Announces Conclusion of Robust Phase III Clinical Program for linagliptin [Press Release]
PRNewswire | 53 days 23 hours 59 minutes ago
...Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S...Corporation (Ridgefield, CT) and a member of the...Wainright, Public Affairs & Communications, BoehringerIngelheim Pharmaceuticals, Inc., +1-203-791...

Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients [Press Release]
PRNewswire | 84 days 16 minutes ago
RIDGEFIELD, Conn., Aug. 30 /PRNewswire/ --

Video: Making Sense of Diabetes Video Contest Asks 'What Does Diabetes Taste, Smell or Sound Like to You?' [Press Release]
PRNewswire | 58 days 23 hours 14 minutes ago
...Pharmaceuticals, Inc. To view the...Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest...Corporation (Ridgefield, CT) and a member of...Public Affairs & Communications of Boehringer Ingelheim...Pharmaceuticals,Inc., ann.wainright...

Boehringer Ingelheim Animal Health Closes Deal to Acquire a Significant Portion of the Fort Dodge Animal Health Business From Pfizer [Press Release]
PRNewswire | 26 days 17 hours 55 minutes ago
...Ingelheim Vetmedica, Inc., announced today that...Ingelheim Vetmedica, Inc. (St. Joseph, MO...based in Ridgefield, CT and a member of the Boehringer...Kunkel, Public Affairs & Communications of BoehringerIngelheim Pharmaceuticals, Inc., +1-203-798...

Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations [Press Release]
PRNewswire | 110 days 23 hours 45 minutes ago
RIDGEFIELD, Conn., Aug. 3 /PRNewswire/ -- Boehringer Ingelheim announced today at the International Association for the Study of Lung Cancer's 13th World Conference on Lung Cancer (WCLC), San Francisco, CA, the initiation of a Phase III clinical study of BIBW 2992 as first-line treatment in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. BIBW 2992 is the first orally-administered irreversible dual inhibitor of EGFR and HER2,(1) to reach Pha...

Boehringer Ingelheim Animal Health Enters into Agreement to Acquire Certain Assets of Fort Dodge Animal Health from Pfizer [Press Release]
PRNewswire | 61 days 14 hours 45 minutes ago
...Ingelheim Vetmedica, Inc., announced today that...Ingelheim Vetmedica, Inc. (St. Joseph, MO...based in Ridgefield, CT and a member of the Boehringer...Kunkel Public Affairs & Communications Boehringer Ingelheim Pharmaceuticals, Inc. Phone: 203.798...

Editorial Feature: Optometry Times Applies for BPA Worldwide Business Publication Membership [Press Release]
MarketWire | 16 days 15 hours 42 minutes ago
SHELTON, CT -- (Marketwire) -- 11/05/09 -- Optometry Times has applied for business publication membership in BPA Worldwide. The magazine is published by Advanstar Communications Inc (Iselin, NJ).

Frontier Communications Reports Solid 2009 Third-Quarter Results [Press Release]
Business Wire | 19 days 17 minutes ago
Frontier Communications (NYSE:FTR) today reported third-quarter 2009 revenue of $526.8 million, operating income of $172.5 million and net income attributable to common shareholders of Frontier of $52.2 million.